Abstract
This is the report for professionals interested to grasp the field of
apoptopic drug targets in oncology and at the same time have an extensive R&D
overview of lung cancer and melanoma. This extensive 540+ pages report
compiles and analyzes Apoptosis, the type of death about whose genetically
controlled pathways we know the most, and further give an in depth analysis in
two key oncology areas; Breast- and Prostate cancer BioSeeker has surveyed
apoptopic drugs in oncology and identified 119 drug targets, belonging to 114
drugs. 90 unique drug target combinations, each comprised of a different
collection or mix of individually defined targets, for 114 apoptopic drugs
designed for the treatment of 48 different cancer indications.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of apoptopic drugs. No less than 452 protein-protein interactions were
recognized among 96 of the 119 included apoptopic drug targets.
The report by the numbers
- A hundred different tables. Includes more than 1,500 active links to
related resources on the Internet
- 114 apoptopic drugs, under development by 87 investigators, are included,
covering more than 430 developmental projects in cancer
- 119 Unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other apoptopic
drug targets, linked cancer indications, drugs under development, compound
types, presence in the Cancer Genome Project etc.
- 90 Unique drug target combinations of apoptopic drugs
- 452 protein-protein interactions among apoptopic drug targets
- Extensive pathway analysis of drug targets
The risk of malignant melanoma has more than doubled in the past decade. The
incidence of melanoma is rising faster than that of any other cancer. This
in-depth analysis of the progress of melanoma R&D and current treatment
strategies is one of the most extensive reports available in this field. No
less than 68 approved drugs and drug candidates have been studied. Progress
profiles and structured information will allow you to pin-point your
knowledge-base in a most cost-effective way. New interesting phase III studies
have been initiated. By gathering information around most drugs under
development for melanoma and specially the late stage pipeline it has been
clear that four major therapeutic strategies generated the most interesting
data.
Lung cancer is the third most common malignant disease and the first leading
cause of cancer death in the western world. Yet platinum agent constitutes the
current mainstay of front-line metastatic lung cancer treatment. There are
currently two platinum-based compounds that are marketed and clinically used
worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs
are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build
the first-line treatment options. Several different studies have been
comparing or are comparing differ combinations of these drugs. Lately
gefitinib, pemetrexed and erlotinib have entered the market and are initially
used in second or third-line treatments. In this report we are not only
describing the progress of different combinations of approved drugs but as
well the progress of 21 late stage drug candidates are described and analyzed.
Progress profiles and structured information will allow you to pin-point your
knowledge-base in a most cost-effective way. By gathering information around
most drugs under development for lung cancer and specially the late stage
pipeline it is has been clear that four major therapeutic strategies generated
most interesting data. With this report you will be able to track down and
foresee activities associated with the development of new treatments for lung
cancer. According to market analytical studies, the NSCLC drug market is
predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will
experience generic erosion and three major chemotherapy drugs go off patent
before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb' s Paraplatin
(carboplatin) and Eli Lilly' s Gemzar (gemcitabine).
| 
View Cart
